Our mission is to leverage scientific advancements in creating autologous biologic preparations, which enable physicians to optimize the practice of regenerative medicine.
Greyledge Technologies has created a technology platform that allows physicians the opportunity to integrate autologous PRP and BMCC biologic preparations into their practice. The process relies on the use of a controlled laboratory setting, coupled with a fully documented and validated sample analysis.
Greyledge Technologies was established to meet emerging physician demands to facilitate and utilize mechanisms of natural healing to augment and/or support repair of damaged tissue. Greyledge has developed novel, manual laboratory-based methods to process autologous whole blood and bone marrow tissues to produce injectable or implantable bioactive preparations. Each biologic preparation is carefully analyzed prior to return to the patient to ensure quality and to meet physician-specified compositions. Greyledge’s approach is flexible, allowing physicians to optimize their practice of medicine through maintaining the highest standards in preparing and analyzing autologous PRP and BMCC preparations.
Founder and Chief Executive Officer
Greyledge operations are currently being led by company Founder and CEO – David Karli. He is responsible for all aspects of company development, including the integration of a strong team of professionals to support Greyledge’s innovative approach to regenerative medicine.
Vice President Research and Regulatory Affairs
Dr. Sand recently joined the company to support on-going commercialization efforts, as well as initiate an active research program to advance the company’s technology platform.
Gary recently joined the company to preside over day-to-day business operations and direct future strategic initiatives. Mr. Peterson has spent over 40 years in the medical device, health services and finance business.